This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Rituximab in the Treatment of Graves' Disease

This study has been completed.
Information provided by:
Odense University Hospital Identifier:
First received: September 6, 2005
Last updated: October 5, 2006
Last verified: October 2006


In a phase II pilot study encompassing 20 patients with Graves’ disease to evaluate the effect of rituximab:

1. Biochemically as assessed by markers of disease activity ( free T4, free T3, TSH, TSH-receptor antibodies, anti-TPO)

Condition Intervention Phase
Graves´ Disease Thyroid Associated Ophthalmopathy Drug: Methimazole Drug: Rituximab Biological: Immunization with various vaccines Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: B Cell Depletion With the Anti-CD20 Monoclonal Antibody Rituximab in the Treatment of Graves' Disease

Resource links provided by NLM:

Further study details as provided by Odense University Hospital:

Primary Outcome Measures:
  • Time to relapse after cessation of treatment judged at 1, 3, 6, 9 and 12 months post cessation.

Secondary Outcome Measures:
  • Safety
  • Changes in autoantibodies (monthly)
  • Immunological changes (monthly)
  • Response to vaccines (1 month post-immunization)

Estimated Enrollment: 20
Study Start Date: June 2003
Estimated Study Completion Date: October 2006
  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Graves´ disease
  • Adequate anticonception in women.

Exclusion Criteria:

  • Performance status >2
  • Previous rituximab treatment
  • Immunosuppressive treatment
  • Serious concomitant disease
  • Active infections
  • Pregnancy / breast feeding.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00150111

Department of Endocrinology, Odense University Hospital
Odense, Funen, Denmark, 5000
Department of Hematology, Odense University Hospital
Odense, Denmark, 5000
Sponsors and Collaborators
Odense University Hospital
Principal Investigator: Daniel El-Fassi, MD Odense University Hospital
  More Information

Publications: Identifier: NCT00150111     History of Changes
Other Study ID Numbers: 014
Study First Received: September 6, 2005
Last Updated: October 5, 2006

Keywords provided by Odense University Hospital:
Graves disease
B lymphocyte depletion

Additional relevant MeSH terms:
Graves Disease
Graves Ophthalmopathy
Eye Diseases
Orbital Diseases
Thyroid Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Eye Diseases, Hereditary
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents processed this record on September 20, 2017